Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor? by Claus, Benedikt Bernd et al.
ORIGINAL RESEARCH
published: 03 December 2020
doi: 10.3389/fpsyt.2020.598150






Columbia University Irving Medical
Center, United States
David Gorelick,






This article was submitted to
Addictive Disorders,
a section of the journal
Frontiers in Psychiatry
Received: 23 August 2020
Accepted: 09 November 2020
Published: 03 December 2020
Citation:
Claus BB, Specka M, McAnally H,
Scherbaum N, Schifano F and
Bonnet U (2020) Is the Urine







Is the Urine Cannabinoid Level
Measured via a Commercial
Point-of-Care Semiquantitative
Immunoassay a Cannabis Withdrawal
Syndrome Severity Predictor?
Benedikt Bernd Claus 1, Michael Specka 2, Heath McAnally 3, Norbert Scherbaum 2,
Fabrizio Schifano 4 and Udo Bonnet 1,2*
1Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Evangelisches Krankenhaus Castrop-Rauxel,
Academic Teaching Hospital of the University of Duisburg-Essen, Castrop-Rauxel, Germany, 2Department of Psychiatry and
Psychotherapy, Faculty of Medicine, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany, 3Department of
Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA, United States,
4 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical
Sciences, University of Hertfordshire, Hatfield, United Kingdom
Background: For cannabis-dependent subjects, the relationship between cannabis
withdrawal syndrome (CWS) severity and the urine cannabinoid concentrations
are unclear; we investigated this using a commercial point-of-care (POC) enzyme
immunoassay detecting 11-nor-9-carboxy-Delta-9-tetrahydrocannabinol (THC-COOH).
Methods: Observational study of 78 adult chronic cannabis-dependent subjects
assessed over a 24-day inpatient detoxification treatment, with 13 serial measurement
days. Repeated Measures Correlation and Multilevel Linear Models were employed.
Results: Absolute urinary THC-COOH levels significantly correlated with Marijuana
Withdrawal Checklist (MWC) scores across the entire study duration (r = 0.248; p <
0.001). Correlation between serial creatinine-adjusted THC-COOH ratios and serial MWC
scores emerged as significant only in the sample with higher MWC scores (>11 points) at
admission (n = 21; r = 0.247; p = 0.002). The aforementioned significant relationships
have persisted when replacing the absolute THC-COOH-levels with the (relative) day-
to-day change in urinary THC-COOH levels. MWC scores were significantly correlated
with the Clinical Global Impression-Severity (CGI-S; r = 0.812; p < 0.001). Females
showed a significantly slower decline in urine THC-COOH levels and prolonged CWS
course characterized by substantial illness severity (per CGI-S), occurring in nearly 30%
of cases.
Conclusion: Urine cannabinoid levels (THC-COOH) determined by
POC assay significantly predicted CWS severity (moderate correlation),
guiding detoxification treatment duration. In patients with MWC > 11
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points upon admission, creatinine-adjusted THC-COOH ratios also significantly predicted
CWS severity—again with moderate effect size. Females showed prolonged urinary
THC-COOH elimination and cannabis withdrawal.
Keywords: urinary 11-nor-9-carboxy-delta9-tetrahydrocannabinol, gender effect, cannabis withdrawal syndrome
subtypes, protracted withdrawal syndrome, inpatient detoxification treatment
INTRODUCTION
The abrupt cessation of frequent cannabis intake is followed by
a cannabis withdrawal syndrome (CWS), primarily presenting
with emotional and behavioral symptoms (1–3). In US adults
frequently using cannabis, the prevalence of CWS was 12.1% (4).
Moreover, CWS is a key component of the cannabis dependence
syndrome (CDS) as defined in ICD-10, with nearly 90% of
these individuals displaying clinically relevant CWS (5). The
cannabinoid receptor type 1 (CB1) is thought to play a major
role in CWS occurrence (3, 6, 7). Discontinuation of synthetic
cannabinoids (which are generally full CB1 agonists) (6) leads
to a similar withdrawal syndrome (3); conversely, CB1 agonists
alleviate CWS symptoms (3, 7).
Over the past 20 years, clinical characteristics of CWS
have been described in many out- and inpatient as well as
epidemiologic studies (1, 3). Operationalized CWS criteria
were first provided in DSM-5 (8) and await revision and
expansion in ICD-11 (3), with the magnitude of CWS severity
generally associated with the extent and duration of cannabis
use before quitting (1, 3, 7). The severity of CWS in heavy
users is comparable with the burden of a moderate major
depressive episode, a moderate alcohol withdrawal syndrome
(9) or tobacco withdrawal (10), at times requiring in- (9) or
outpatient (10) treatment.
The main psychotropic agent of natural cannabis is delta-
9-tetrahydrocannabinol (THC) which is a CB1 partial agonist
(3, 6). Main metabolites of THC include the psychotropic,
water-soluble 11-hydroxy-delta-9-tetrahydrocannabinol (THC-
OH), and the nonpsychotropic and lipophilic 11-nor-9-carboxy-
delta-9-tetrahydrocannabinol (THC-COOH) (11). THC-COOH
undergoes conjugation with glucuronic acid prior to excretion
in the urine (12, 13) where it serves as a biomarker of cannabis
use in commercial point-of-care drug screening tests (14, 15).
However, urine THC-COOH levels alone cannot be used to
determine either the timeframe or the amount of the last cannabis
use (11, 16, 17). In Germany, where inpatient detoxification
of cannabis users undergoing significant levels of CWS is
supported by statutory health insurance (3), the termination of
the inpatient detoxification treatment phase is often empirically
determined by the observation of consistent urine THC-COOH
levels below a cutoff point of 50 ng/ml (the sensitivity limit of
most immunoassays) (14) which corresponds to the US federally
mandated immunoassay cutoff concentration (18). However, it
is unclear whether levels of this biomarker—as measured by
point-of-care testing (POCT)—are really associated with CWS
severity in clinical practice, which influences treatment decisions
regarding discharge and subsequent outpatient rehabilitation
treatment for CDS (3). Greater-severity CWS is not only
associated with increased likelihood of CDS but also with
increased comorbidity and negative psychosocial outcomes (1–
4). The answer to the question of whether an easily determined
POCT biomarker predicts CWS severity thus assumes greater
importance in the context of resource allocation.
Toward that end, we investigated the correlation between
the clinical CWS course of cannabis-dependent persons seeking
inpatient detoxification treatment and the trends of their
urine cannabinoid levels as measured by the semiquantitative
DRI R© Cannabinoid Assay (15). This inpatient environment
allowed for good control of major potential confounding
factors such as cannabinoid relapse, concomitant hidden drug
or alcohol use, and environmental psychosocial stress and
comorbidities (9). We also examined the potential confounding
issues of intentional dilution and adipose tissue cannabinoid
redistribution by assaying for both creatinine- and BMI-
normalized urine cannabinoid levels (11–13).
METHODS
Study Design, Participants, and Eligibility
Criteria
This prospective observational study was conducted from 2008
to 2014 in an inpatient unit for detoxification from alcohol,
prescription, and recreational drug abuse including cannabis
at the Psychiatric University Hospital in Essen (LVR-Klinikum
Essen), Germany. Adult detoxification-seeking patients who
had a cannabinoid-positive urine screen upon admission were
eligible. Only those patients who (a) were older than 18 years,
(b) were diagnosed with cannabis dependence according to ICD-
10 (19), (c) had used cannabis by inhalation daily or near-
daily during the 6 months before admission, (d) reported use
of cannabis within the 24 h prior to admission, (e) had used no
other psychotropic substances (apart from tobacco) during the 4
weeks prior to admission, (f) presented with no active comorbid
psychiatric or somatic disorder requiring treatment, (g) were
familiar with the German language, and (h) gave their written
informed consent were retained in the study. Inpatient treatment
was scheduled for up to 24 days; however, patients could be
discharged earlier based upon a shared patient/staff decision,
when both parties agreed that the individual’s psychiatric and
somatic condition had improved to the point that primary or
secondary care would be sufficient for continuation of treatment.
In some cases, after inpatient stabilization, patients were referred
to rehabilitation clinics for further treatment and support.
Exclusion Criteria
Patients with documented (e.g., through breath analysis or
urinalysis) relapse to use of cannabis or other substances
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including alcohol were excluded from the study. If there was
reasonable suspicion of undisclosed Z-drugs (e.g., zolpidem,
zaleplon, or zopiclone) or new psychoactive drugs (20), special
urinalysis or serologic assays were performed and/or sent for
detailed or confirmatory analysis to MVZ Synlab Leverkusen
GmbH, Leverkusen, Germany, or the Division of Forensic
Medicine at the University of Duisburg-Essen, Germany.
A ratio of 1.5 or greater between two serial creatinine-
normalized urine THC-COOH values was interpreted as
indication of relapse to marijuana use (21). In such cases, as
previously described (9), blood THC-OH concentrations were
assessed by gas chromatography-mass spectroscopy (GC-MS)
for confirmation, and when an increase over admission baseline
THC-OH was confirmed, the patient was excluded from the
study on the basis of apparent cannabis relapse (9).
Dropout Criteria
Dropouts included (a) premature self-discontinuation of
treatment, (b) withdrawal of study participation consent, or (c)




The multimodal inpatient treatment program consisted of
a diverse regimen including regular medical assessments,
individual and group psychotherapeutic sessions based upon
motivational enhancement, cognitive-behavioral treatment
elements and psychoeducation, physical and occupational
therapies, and social counseling. In addition, the option for
postdischarge transfer to a long-term rehabilitation program
was offered to all patients. When patients showed distressing
withdrawal symptoms such as anxiety, dysphoria, restlessness,
or sleep disturbance, the nursing staff was allowed to administer
escalating doses of gabapentin (22) (up to 600mg q.i.d) or
chlorprothixene (up to 50mg q.i.d.) as medication-on-demand
(PRN). For potential subanalysis purposes, an equipotency
ratio assuming 50mg chlorprothixene equivalent to 400mg
gabapentin was used.
Measurements
Upon admission to detoxification treatment, a structured
interview was administered to all patients to determine
sociodemographics, addiction-related information (e.g., age at
first cannabis use, amount and duration of daily cannabis
use, other comorbid substance abuse), psychiatric and other
relevant medical and social information. Substance use during
the previous 6 months was assessed using a timeline follow-back
interview (23). Body mass index (BMI) was determined upon
admission (day 1). During detoxification treatment the severity
of CWS was measured by a modified version of the Marijuana
Withdrawal Checklist (MWC) (9, 24) and the Clinical Global
Impression scale-Severity of Illness (CGI-S) (25). In its original
version, theMWC consists of 10 symptoms (craving for cannabis,
irritability, nervousness/anxiety, restlessness/tension, depression,
anger/aggression, sleeplessness, strange dreams, loss of appetite,
headache) which are rated on a 4-point scale (0 = not at all, 1
= mild, 2 = moderate, 3 = heavy) (25). Consistent with prior
investigation carried out by our group (3, 9) two more clinically
relevant and validated (2, 7, 10) symptoms (sweating and nausea)
were added to the original MWC. The MWC was administered
as a face-to-face interview by UB or by other trained physicians.
The MWC, CGI-S, and urine drug testing (see below)
were performed at admission, on the next day (day 2) and
subsequently every other second day until the end of the inpatient
treatment period. Potential relapses were assessed duringmedical
reviews with the help of breathalyzer and random urine drug
screens (see “Exclusion Criteria”).
Urine Cannabinoid-Analysis and Related
Ratios
In clinical practice, urinary immunoassays (IA) provide
immediate confirmation and detection of reported and
unreported drug use, respectively (11, 14). Commercially
available cannabis IA show good specificity for cannabinoids
with minimal false-positive cross-reactivity from other
substances (11). For this investigation, we utilized a convenient
semiquantitative POCT instrument, the DRI R© Cannabinoid
Assay (“DRI R©” (15), analyzed by a Beckmann-Coulter AU 400
chemistry analyzer.
DRI R© identifies the following cannabinoids: THC, THC-OH,
THC-COOH, 11-OH-delta-8-THC-COOH, 8-beta-OH-delta-
9-THC, 8-beta-11-OH-delta-9-THC, and cannabidiol. DRI R©
provides a cannabinoid measurement range between 0 and
200 ng/ml if the analyzer is calibrated using the 200 ng/ml
THC-COOH calibrator (15). Using Dri R© Drugs of Abuse
Immunoassays for urine screening, a sensitivity and a specificity
of 91 and 96%, respectively, were observed for the detection
of cannabinoids (THC-COOH, Assay cut off 4 IA-units)
(26). Using a 50-ng/ml THC-COOH cutoff calibration, DRI R©
has demonstrated 100% accuracy verified by GC-MS with a
15 ng/ml cutoff (15). We therefore used the 200-ng/ml calibrator
recommended by the manufacturer and a 50-ng/ml cutoff.
For simplicity, the urine cannabinoid levels as measured by
DRI R© were here reported as THC-COOH levels (see also
below in the “Discussion—Limitations” section). To account
for the role of body fat in storage and multicompartmental
pharmacokinetic redistribution of the lipophilic THC molecule
andmetabolites (11, 12), serial THC-COOH concentrations were
adjusted for BMI (B-N-THC-COOH) and reported as nanograms
per milliliter THC-COOH per kilogram square meter. To
adjust for dilution or concentration of urine specimens (11),
we furthermore calculated creatinine-normalized THC-COOH
concentrations (C-N-THC-COOH) by dividing all serial THC-
COOH concentrations by the urine creatinine concentration
(g/L) with results reported in nanograms THC-COOH per
milligram of creatinine (16). Creatinine levels were determined
by IA from the same urine sample assayed for cannabinoids,
and any sample with a creatinine concentration <20 mg/dl was
considered to be adulterated (11).
Statistics
For the intention-to-treat (ITT) analysis, we used descriptive
statistics. Repeated Measures Correlation (rmcorr) for the
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TABLE 1 | Sociodemographic and clinical variables of the ITT sample of cannabis-dependent subjects admitted for an inpatient detoxification treatment.
Study population N % Median Mean (SD) Min. Max.
Age (years old) 78 100 24 26.4 (7.0) 18 51
Females 18/78 23
BMI (kg/m²) 73 93.6 22.4 22.5 (3.0) 16.5 29.5
Age (years) at first-ever cannabis use 73 93.6 17 18.0 (4.8) 9 33
Duration (years) of cannabis use prior to admission 73 93.6 8 9.4 (2.2) 0.25 36
Daily amount (g) of cannabis inhalation during the 6 weeks prior to admission 73 93.6 2 2.2 (1.5) 0.5 10
(Tobacco) cigarettes per day 72 92.3 20 18.6 (7.8) 0a 40
Patients requiring PRN medication 44 56.4
Patients without educational qualifications 04 5.1
Patients with primary school education 31 39.7
Patients with secondary school education 18 23.1
Patients with general university entrance certificate (Abitur) 05 6.4
Patients having completed vocational training 26 33.3
Unemployed patients 38 48.7
Patients with a history of psychiatric comorbidity 33 42.3
Patients with a history of somatic comorbidity 4 5.1
aThree patients reported nil use of nicotine.
estimation of correlations between two measures being recorded
at multiple time points (27) was used to analyze the relationship
between urine THC-COOH levels (or B-N-THC-COOH or
C-N-THC-COOH ratios) and MWC scores across the study.
Furthermore, we investigated the relationship between day-
to-day change in urinary THC-COOH (delta THC-COOH)
and MWC-scores (see Supplementary Material). For the
investigation of influences on the temporal course of these
measurements, we used Multilevel Linear Models (MLM) (28).
The following control variables (possible confounders) were
included in the model: age, gender, age at index cannabis use,
daily amount and duration of cannabis inhalation prior to
admission, prior amounts of daily cigarettes, prior psychiatric
comorbidity (yes or no), and in addition, the daily gabapentin
dose (22). In the MLM framework, we observed multiple
measurements (level 1) for multiple participants (level 2) (28).
We also performed subgroup analyses as well based on
whether patients presented with low (2–11 points) or high (12–21
points) MWC scores at admission.
With ongoing attrition of patients no longer suffering
from significant CWS and thus leaving treatment, we noted
an inflection point at day 16 with significant increases in
average CWS (as well as THC-COOH levels) seen among
patients remaining in treatment at that point (Figure 2;
Supplementary Figure 2). As such, we chose to stratify the
sample into “early” vs. “late” discharge subgroups based on
when their discharge occurred in relationship to that mark.
Comparisons between early and late discharged patients were
carried out using Welch’s t tests and χ² tests as well as MLM
regression analysis (see Supplementary Material).
For all tests, a significance criterion of p < 0.05 was used.
We used IBM SPSS Statistics 21 and R (29) for our analyses,
with the R package nlme (30) for MLMs. Correlation coefficients
(Pearson’s r) were defined as small (r > 0.1), medium (r > 0.2),
and large (r > 0.3) (31).
RESULTS
Sample
During the 6-year study period, 2017 detoxification treatments
were carried out on the ward, with 735 of these admissions
characterized by cannabinoid positivity on initial urine screen
and 97 of these meeting the inclusion criteria. Eight of
these however were repeat admissions of the same individual
(doublets) and 11 patients declined participation, yielding a
study population of 78 patients (all white) being included in
the ITT analysis. Sociodemographic and clinical variables are
shown in Table 1. Mean (SD) BMI was not significantly different
between females [22.4 (2.93)] and males [22.5 (2.99); t(24.44) =
−0.136, p = 0.893]. Psychiatric comorbidity histories included
borderline personality disorder, major depression, panic disorder,
insomnia, and ADHD. Somatic comorbidities included allergic
bronchial asthma, gastro-esophageal reflux disease, ulcerative
colitis, and arthropathies not otherwise specified. Of these,
none worsened during the detoxification treatment to an extent
requiring further treatment.
Treatment Durations and Attrition Rate
Nine (11.5%) participants dropped out of the study. All of
these patients discontinued inpatient treatment prematurely,
within days 4–13; remaining patients (n= 69, 88.5%) underwent
planned discharge. The attrition rate (dropouts plus regularly
discharged patients) is illustrated in Figure 1. The mean (SD)
inpatient detoxification lasted 14.6 days (6.5), with a median of
14 days, and minimum of 6 and maximum of 24 days.
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FIGURE 1 | The number of serial investigations across the study. The number
of patients remaining in the study is equivalent to the maximal number of any
measure at any given day. Day 1, day of admission. At every study day, MWC




Most treatment completers (n = 37, 47.4% of all patients) were
referred to an outpatient program at the same clinic (32) while
21 patients (26.9%) were referred to a specialized long-term
rehabilitation facility.
Course of Measured Variables
Figure 1 shows the number of the serial MWC ratings and
urinary THC-COOH measurements across the study. Their
decreasing numbers over time reflect the nine dropouts and
regular discharge of patients as outlined above in Figure 1.
Figure 2 shows the values of the measurements across the study.
The striking transient deterioration between days 16 and 22
correlated with the removal of a “dilution effect” exerted by
improved patients leaving treatment prior to day 16.
Relationship Between CWS and Urine
THC-COOH Across the Study
Using rmcorr, which analyzes the relationship betweenMWCand
the respective metabolite ratios at every point of measurement,
positive correlation was identified between MWC and THC-
COOH (r = 0.248 [0.152, 0.339], df = 388, p < 0.001). A
significant positive correlation was also found between MWC
and B-N-THC-COOH (r = 0.249 [0.154, 0.341], df = 388, p <
0.001). The association between MWC and C-N-THC-COOH
was not significant (r = 0.096 [−0.004, 0.195], df = 382, p
= 0.059).
To account for possible confounding variables (listed above
in the “Statistics” section), we used MLM. The random
intercept and random slopes models were in all cases superior
to the intercept-only and random intercept-only models
(see “Statistics”). The chosen random intercept and slopes
models’ calculations provided the following results: a significant
association was confirmed between MWC scores and THC-
COOH ratios (b = 0.026 [0.014, 0.037], p < 0.001). The models
also demonstrated a significant positive association between
MWC scores and B-N-THC-COOH (b = 0.572 [0.338, 0.805],
p < 0.001). Finally, the relationship between MWC scores and
C-N-THC-COOH ratios also emerged as significant (b = 0.005
[0.0002, 0.009], p = 0.040), with the daily gabapentin dose being
the decisive factor, b= 0.001 [0.0005, 0.002].
Influence of Admission (Baseline) CWS
Severity
For those patients (n = 21) who presented with high CWS
severity (12–21 MWC points) upon admission, C-N-THC-
COOH values significantly correlated with the MWC scores
across the whole study (r = 0.247 [95% CI, 0.094 to 0.39]; p =
0.002). This association remained significant after incorporating
the control variables into the model (b = 0.011 [95% CI, 0.003
to 0.019]; p = 0.006). Conversely, for those 46 subjects who
presented at admission with low CWS severity (2–11 MWC
points), no significant correlation was identified with C-N-THC-
COOH ratios across the whole study (r = −0.043 [95% CI,
−0.173 to 0.088]; p = 0.519; b = 0.0004 [95% CI, −0.005 to
0.005]; p= 0.891).
Predictors of CWS and Urine THC-COOH
Values (as well as the Ratios)
To further clarify the above-described associations, we analyzed
time course and a range of remaining control variables (see
“Methods—Statistics”) as possible predictive factors influencing
MWC scores, urine THC-COOH levels, C-N-THC-COOH,
and B-N-THC-COOH ratios. Again, the random intercept and
random slopes models were in all cases superior to the other
models of MLM; the respective results of these models are
presented below.
MWC Scores
MLM revealed the factor “time” to be significant (p= 0.009) with
a negative regression coefficient (b) of−1.078 [95% CI,−1.873 to
−0.284]. In other words, the MWC score decreased 1.08 points
on average from measurement to measurement when all control
variables were held constant. The other significant association
noted was that between MWC scores and Gabapentin dose (b
= 0.001 [95% CI, 0.0006 to 0.002]; p = 0.003), i.e., the higher
the daily gabapentin dose, the higher the MWC scores. The
remaining variables did not significantly predict the MWC score.
Urine THC-COOH Levels
Time was identified as a significant factor (p = 0.003) in
predicting urine THC-COOH levels with a negative regression
weight (b) of −13.562 [95% CI, −22.492 to −4.632]. In other
words, with remaining variables being held constant, THC-
COOH ratios decreased from measurement to measurement by
over 13 points on average. Age at first-ever cannabis use also
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FIGURE 2 | Course of the detoxification treatment as measured (A) via the Marijuana Withdrawal Checklist (MWC); (B) Clinical Global Impression-Severity (CGI-S); (C)
levels of urinary 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (Urine THC-COOH); (D) creatinine-normalized THC-COOH (C-N-THC-COOH); and (E)
BMI-normalized THC-COOH (B-N-THC-COOH). SE, standard error. The striking transient deterioration between days 16 and 22 correlated with the removal of a
“dilution effect” exerted by improved patients leaving treatment prior to day 16.
emerged as a significant predictor (b = −3.391 [95% CI, −6.491
to −0.291]; p = 0.035) with higher THC-COOH ratios for those
with an earlier onset of cannabis use. The interaction between
time and gender was significant as well (b = −4.549 [95% CI,
−8.721 to −0.377]; p = 0.035), indicating a faster decline of
THC-COOH levels in male patients.
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C-N-THC-COOH Ratios
For all urine samples, creatinine was >20 mg/dl. Neither “time”
nor the other control variables influenced the C-N-THC-COOH
ratios significantly.
B-N-THC-COOH Ratios
The factor “time” was significant (p < 0.001) with a negative
regression weight (b = −0.731 [95% CI, −1.154 to −0.308]). In
other words, with the other variables held constant, B-N-THC-
COOH ratios decreased from measurement to measurement by
0.73 points on average. The interaction between time and gender
was also significant (b = −0.219 [95% CI, −0.417 to −0.020]; p
= 0.033), indicating a faster decline of B-N-THC-COOH levels
in males. The remaining control variables did not influence the
B-N-THC-COOH ratios significantly.
Using the Day-to-Day Change in Urinary
THC-COOH Levels (Delta
THC-COOH-Levels) Instead of the
Absolute THC-COOH Levels
All aforementioned significant relationships and influences
identified by using the absolute urinary THC-COOH levels as
outcome variable were confirmed by substituting these by using
the relative delta THC-COOH levels (Supplementary Figure 1).
The other results were also not altered as the relationships and
influences remained insignificant (see Supplementary Material).
Relationship Between MWC and CGI-S
Scores
Using rmcorr, a significant correlation between MWC and CGI-
S scores was identified (r = 0.812 [95% CI, 0.776 to 0.843];
p < 0.001). Using MLM to adjust for the influence of control
variables, the relationship between MWC and CGI-S scores
remained significant, with b = 3.310 [95% CI, 2.972 to 3.652],
and p < 0.001.
Early- vs. Late-Discharged Patients
See Supplementary Material.
DISCUSSION
Serial Positive Correlation of Urine
THC-COOH and CWS Across the Study
and Factors Influencing Their Slopes
Individuals seeking inpatient detoxification for their CDS—
without other significant comorbidities/coexisting substance use
disorders—are relatively rare in our experience, as reflected in
the prolonged recruitment and study period of 6 years. To the
best of our knowledge, this study is the first to demonstrate
the significant association between urine THC-COOH levels and
CWS severity, which proved to be a robust finding via regression
analyses, rmcorr and MLM. The strength of the association
however was moderate at best (r = 0.248) and disappeared when
evaluating creatinine-adjusted cannabinoid levels (r= 0.096, p=
0.059). A significant positive correlation however between these
variables (C-N-THC-COOH and MWC) was restored if PRN
medication use was left in the model. As we have also found that
the PRN medication significantly predicted the CWS severity, it
was likely that a significant correlation betweenMWC scores and
C-N-THC-COOH ratios may be observed in patients with high
CWS levels only. Indeed, this was the case in patients with MWC
scores>11 points at admission, again with moderate effect size (r
= 0.247).
The Controversial Role of
Creatinine-Adjusted Drug Screens in
Routine Practice
To reduce the influence of urine dilution upon measured drug
and metabolite values, creatinine adjustment or normalization is
recommended as the scientific standard, including the assaying of
urine THC levels (11). However, such adjustment is not generally
carried out in routine practice, which typically relies only on
threshold or cutoff measurement/detection (33). The reliability
of the urine creatinine level as a “dilution marker” is also limited
by the effects of protein concentration in the diet, muscle mass,
physical activity and even emotional stress, and urine creatinine
level may accordingly vary greatly throughout the day (34, 35).
As such, it must be understood that urine creatinine level at any
given point in time comprises a single “snapshot.”
One could speculate that PRN medication altered urine
concentration by an effect onGFR or solute reabsorption. Neither
mechanism however has been shown at therapeutic doses of
gabapentin or chlorprothixene to the best of our knowledge nor
has an additive osmolar effect (more solute, i.e., gabapentin or
chlorprothixene in the urine).
Gender Effect
Urine THC-COOH levels decreased significantly faster in males,
while females remained longer in the study (i.e., >16 days),
suggesting a protracted withdrawal in females. This is consistent
with previous studies showing worsened CWS levels in females
vs. males (7, 9).
BMI and Other Factors Putatively
Influencing Both CWS- and Urinary
THC-COOH Slopes
The rapid decline in urinary THC-COOH levels in males
appeared to be independent from BMI normalization, and this
may argue against a prolonged redistribution phase of THC
from adipose tissue deposits (13, 14) as the key factor for
delayed urine elimination of THC-COOH (12, 13). Similarly,
no correlation between BMI and plasma THC levels in chronic
cannabis smokers during 7 abstinent days was identified (36).
Female and male BMI levels were not significantly different
in this study population, which may suggest that the suggested
gender-specific differences in both THC elimination and
protracted CWS may not necessarily be the consequence of
body composition differences. Conversely, one could argue that
BMI may not be the best marker to identify the individual
fat proportion and distribution. In order to better characterize
the potential role of adiposity on cannabinoid metabolism and
elimination, alternate methods such as skin caliper testing, Dual
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Energy X-ray Absorptiometry (DEXA), or Magnetic Resonance
Imaging (MRI) might be considered (37).
Neither age, amount, or duration of prior cannabis intake nor
history of comorbidities were shown to influence MWC, THC-
COOH, or their interaction in this study. Furthermore, although
age at initial cannabis use predicted urine THC-COOH levels, it
did not predict either CWS severity or the positive association
between THC-COOH and MWC.
PRN Medication Effectiveness
See Supplementary Material.
Replacing the Absolute THC-COOH Levels
With the Day-to-Day Change in THC-COOH
Levels
Using each day’s absolute THC-COOH level (Figure 2C)
is not the same as day-to-day change in level
(Supplementary Figure 1). It seems plausible that it is the
degree of THC-COOH decline itself, not the absolute level,
that indirectly drives withdrawal [provided that the THC-
COOH decline is closely related with the THC decline which
pharmacologically drives withdrawal (3, 11, 13)]. However,
we found no relevant differences regarding our results when
replacing the absolute THC-COOH levels with the (relative)
day-to-day change in urinary THC-COOH levels as an outcome
variable (see Supplementary Material). In this context, it should
be emphasized that all patients reported that their last cannabis
use had taken place within the last 24 h before admission
(according to our inclusion criteria). Thus, this time span seems
to be appropriate for our accuracy purposes.
Protracted CWS and THC-COOH
Elimination
Most of the study population (e.g., the “early” group; n = 58
including dropouts) had been discharged normally before day
16 due to sufficient clinical improvement levels. Conversely, the
findings of the “late” group (n = 20), presenting with both
considerable CWS intensity and urine THC-COOH levels, may
indicate the existence of a distinct subset of THC users—around
30% in our sample—characterized by a protracted withdrawal
course (38–40). The symptom patterns and trajectories of
these two groups are consistent with those of the previously
postulated CWS subtypes A and B (3), respectively. It would
be worth investigating whether genetic variations of cannabis-
metabolizing enzymes account for these subtypes’ differences
(13, 41).
In our late-discharged group, the average THC-COOH values
did not drop below the cutoff value of 50 ng/ml even after
24 abstinent days. While this is in line with previous findings
(42, 43), it also supports the existence of a special population
among chronic cannabis users with a delayed THC terminal-
phase elimination from the body (16, 43–46). While prolonged
CWS courses have previously been described and ascribed to
psychiatric comorbidities (39, 40), our late group showed no
such association with psychiatric comorbidity nor with age nor
cannabis history data. What we did find was a disproportionate
female preponderance within the late group, with increased
urine THC-COOH levels, but not with MWC scores. These
observations are consistent with previous observations of females
experiencing a more complicated CWS than males (3, 7). An
alternative explanation would be that the patients in the late
group had consumed cannabis during the study period; the
likelihood of such occurrence was however here minimized
by the measures utilized to detect possible hidden drug and
alcohol use.
Serial Positive Correlations Between MWC
and CGI-S
The present study confirmed our previous findings that the
MWC score is a valuable predictor of the disease burden
experienced by patients with CDS abstaining from use, as
measured via the CGI-S (9). Notably, in patients with a protracted
CWS (n= 20, 27.4%), the average CGI-S score did not drop over
time below the 4-point mark, indicating: “. . . overt symptoms
causing noticeable but functional impairment or distress. . . ” (25).
This demonstrates a persistent illness burden in a subgroup of
heavy/long-term cannabis users despite detoxification, who may
require more intensive postdetox rehabilitation (3). It could be
argued that durable executive and social deficits (47, 48) were the
main factors behind the functional impairment of this (primarily
female) group demonstrating slower elimination of cannabinoids
and protracted CWS, and these phenomena might be amplified
by potential gender differences in the regulation of the brain
endocannabinoid system (7). As a side note, this constellation of
pharmacokinetic and pharmacodynamic differences might also
explain the observation that females seem to progress more
rapidly from first regular cannabis use to cannabis dependence
than males (7).
Cognitive functions of this group may also have been affected
by residual plasma THC [as with more recently abstinent chronic
cannabis users (3, 44)], but this hypothesis is not consistent with
recent findings (49).
Strengths of the Study
This study provides insight into the course of CWS among
treatment-seeking adult CDS patients during detoxification, and
is the first to investigate the feasibility of utilizing a simple urine-
based POCT to prognosticate about the likely severity of CWS.
The sample was relatively large for this type of study, allowing for
adequate study power to investigate not only routine variables
such as gender, but also less frequently considered variables
including BMI, urine creatinine concentration, etc.
Limitations of the Study
Immunoassays are well known to yield false-positive results
(15), and for optimal specificity, more accurate GC-MS assays
should be employed (11, 13). The point of this study however
was to investigate the potential of a convenient, point-of-care,
semiquantitative IA for use under routine inpatient conditions.
Inherent in the methodology therefore is the risk that the
cannabinoids identified measured by the DRI R© test may not
have exclusively comprised THC-COOH. Nonetheless, this main
THC metabolite increases in the urine within a few hours after
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cannabis use, with specificity/accuracy increasing over time,
paralleling the number of abstinent days (11, 12, 49). Although
one could also hypothesize patients’ intentional use of adulterants
to produce false-negative urine screens (50), all patients sought
treatment of their own accord and presented with a high degree
of motivation, lessening the likelihood of such deception.
A ratio of 1.5 (21) for comparison of later-to-earlier
C-N-THC-COOH levels was used here as evidence of
hidden/undisclosed cannabis relapse. Although this value
has been criticized because of its potential low sensitivity, the
utilization of a lower ratio of 0.5 (13, 44) did not alter our results
(data not shown here).
Consistent with other studies focusing on gender effect on
CWS severity (7), we did not control for female participants’
menstrual period phase, which may have influenced CWS
severity levels.
Roughly half of the patients had been discharged by
day 12, which lowers the statistical power over the second
half of the study. However, the utilization of both rmcorr
and MLM regression analyses should reduce inaccuracies
and biases associated with that attrition (27, 28); see also
Supplementary Material—Methods.
Our results are rather specific for detoxification units
in our country which, for cannabis is usually performed
in psychiatric hospitals with similar personnel and material
structures. However, for the general population of cannabis users,
our results may not be representative.
We did not perform a direct analysis of the association
between urine cannabinoid levels (by POCT) and the severity
of CDS or cannabis use disorder (CUD) which should comprise
a future project. It would also be interesting to expand
this investigation to the outpatient treatment arena, where
environmental stress and CWS might be more intense and
prolonged, and might yield a greater association between
urine cannabinoid levels and CWS than the moderate one
demonstrated in this inpatient study. In this context, a more
detailed investigation of the change of the co-use of daily nicotine
alongside further studies to these issues would be particularly
informative as concurrent tobacco use and possible tobacco
withdrawal may modulate the severity of CWS, CDS, and
cannabis use (1, 3, 11). Ignoring concurrent tobacco use is a
major limitation of the present study. The same applies as for the
fact that we did not determine the exact time of the last cannabis
use of the participants, which, however was within the last 24 h
before admission (see inclusion criteria in the “Methods” section
and the section further above where the results after replacing the
absolute THC-COOH-levels with the day-to-day change in THC-
COOH levels are discussed). Self-reported time of last cannabis
use has some limitations. However, using this variable with
more direct pharmacological relationship to the outcome variable
(CWS), even though it has some measurement limitations, might
be a sophisticated alternative to using an objective variable with
assumably weaker pharmacological relationship to the CWS as
we did with defining the date of admission as temporal baseline.
As we used self-reports to inform about remote and recent drug
history, reporting or recall bias might have also influenced our
results. To mitigate this bias for the CWS rating, we performed
MWC face to face as well as the CGI-S.
CONCLUSIONS
Throughout this 24-day study, the urine THC-COOH levels
significantly predicted the severity of CWS, as measured by the
MWC. After creatinine adjustment, serial THC-COOH values
significantly correlated with serial MWC scores only in those
subjects with high MWC scores (>11 points) at admission.
The correlation levels were generally moderate (r ∼ 0.25).
Female gender correlated significantly with both a delayed
decrease in urine cannabinoid levels and with prolonged CWS.
According to the CGI-S, these CWS levels were characterized by
significant illness severity, which is consistent with a previously
postulated “nonpeaking” CWS-subtype B (3). Conversely, those
patients with a nonprotracted CWS showed the typical “peaking”
character of the CWS-subtype A (3), which is more commonly
seen and reported. The levels of MWC and CGI-S were here
strongly correlated (r = 0.81), suggesting that the CDS disease
burden is comparable with that of other medical conditions.
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